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Abstract: Ochratoxin A (OTA), one of the most toxic mycotoxins, can contaminate a wide 
range of food and feedstuff. To date, the data on its conjugates via glucuronidation 
request clarification and consolidation. In the present study, the combined  
approaches of ultra high performance liquid chromatography-tandem mass spectrometry 
(UHPLC-MS/MS), UHPLC-Orbitrap-high resolution mass spectrometry (HRMS) and 
liquid chromatography-multiple stage mass spectrometry (LC-MSn) were utilized to 
investigate the metabolic profile of OTA in rat liver microsomes. Three conjugated 
products of OTA corresponding to amino-, phenol- and acyl-glucuronides were identified, 
and the related structures were confirmed by hydrolysis with β-glucuronidase. Moreover, 
OTA methyl ester, OTα and OTα-glucuronide were also found in the reaction solution. 
Based on these results, an in vitro metabolic pathway of OTA has been proposed for the 
first time. 
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1. Introduction 
Ochratoxin A (OTA), one of the most potent mycotoxins in cereals and related products, is a 
secondary metabolite produced by several Aspergillus species notably A. melleus, A. auricomus,  
A. alliaceus, A. petrakii, as well as Penicillium verrucosum [1]. Because of its acute toxicity like 
nephrotoxicity, hepatotoxicity, teratogenicity and immunosuppression [2–7], OTA has been speculated 
to be associated with chronic renal diseases in humans (Balkan endemic nephropathy, interstitial 
nephritis) [8–11] and was designated by the International Agency for Research on Cancer (IARC) as a 
possible human carcinogen (group 2B) [12]. Based on animal experiments and epidemiological studies 
on humans, OTA has been regulated by legal limits in many countries [13]. A tolerable daily intake 
(TDI) of 5 ng/kg b.w. was derived for OTA on the basis of the lowest observed adverse effect level [14]. 
Contamination of food and animal feed with OTA may result in the presence of residues in edible 
offal and blood serum [15]. Despite efforts to reduce the amount of this mycotoxin in food and animal 
feed, a certain degree of contamination seems unavoidable at present. Also, OTA has been found 
regularly in human biofluids showing the exposure of humans to this mycotoxin [16,17].  
There is a need for a deeper and more comprehensive understanding of toxicological findings in 
animals and extrapolation of the resulting data as reference to human. In this regard, in recent years 
many in vitro and in vivo kinetics and metabolic studies have been performed to provide information 
on its toxicology and food safety assessment [18–20]. OTA can be transformed by hydrolysis, 
hydroxylation and oxidation into a series of metabolites, i.e., OTα, 4-OH-OTA, opened-OTA and 
ochratoxin quinone [19,21–26]. Moreover, one of the most important metabolisation reactions is 
glucuronidation, mainly in liver microsomes. Some other mycotoxins have been thoroughly 
investigated. Deoxynivalenol (DON) can be metabolized into DON-3-glucuronide and  
DON-15-glucuronide, which account for about 91% of total DON excreted in human urine [27]. The 
excretion rate of zearalenone (ZEN) was about 9.4%, also mainly as glucuronide [28,29]. These 
glucuronides have been successfully employed as biomarkers for assessment of human mycotoxin 
exposure [30,31]. With regard to OTA, at the cellular level, endogenous glucuronic acid can be 
conjugated to the phenolic group or carboxylic group under the catalytic reaction by  
uridine-diphosphate glucuronosyltransferase (UGT), which is a membrane bound microsomal enzyme 
adjacent to CYP [20]. OTA-conjugates have been detected in liver (8%–17%) and intestinal tissue 
(6%) [32]. Interestingly, the presence of glucuronide conjugates was also reported in bile of pigs upon 
feeding with OTA contaminated feed [33]. However, in all these reports, OTA-glucuronides were 
determined indirectly by using β-glucuronidase hydrolysis. No direct or definite evidence for the 
formation of OTA-glucuronides as well as complete chemical configurations are available. For 
example, Gross-Steinmeyer et al. did not observe any OTA glucuronide conjugates in in vitro 
experiments with rat and human hepatocytes [34].  
These in vivo and in vitro data indicate that relevant data on OTA glucuronidation are still missing. 
Therefore, the purpose of this present work was to further clarify the formation of OTA metabolites by 
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rat microsomal preparations and to clearly identify the structures of these metabolites to propose the 
major metabolic pathways of OTA in rat liver microsomes. 
2. Results and Discussion 
Metabolic profiling, focusing on metabolites of targeted analytes, provides important information 
on in vivo biotransformation, which is useful in toxicity testing. To identify the metabolites of OTA, 
liquid chromatography–mass spectrometry LC-MS analyses of reaction mixtures 1, 2, 3 and 4 were 
performed first. The full scan chromatogram of the Reaction 1 solution under positive electrospray 
ionization mode (ESI+) mode is shown in Figure 1 and is similar to that of Reaction 2, which indicates 
that alamethicin does not affect the yield of OTA glucuronides in the current reaction even though it 
should be used in the glucuronidation of T-2 and HT2 [35]. Four new peaks with retention times at 
7.751 min (Compound 1), 8.536 min (Compound 2), 8.733 min (Compound 3) and 11.012 min 
(Compound 4) were evident while they could not be found in control incubations (Reactions 3 and 4). 
Special attention should be paid to the fact that OTB existed in Reactions 1, 2 and 3 with the same 
peak area. After direct injection of the standard solution of OTA, a similar amount of OTB was also 
detected, suggesting that OTB was the impurity in the standard solution but not formed by 
dechlorination of OTA. 
Figure 1. Full scan chromatograph of the Reaction 1 solution in positive electrospray 
ionization (ESI+) mode. 
 
2.1. Compound 1 
The negative full-scan mass spectrum showed a signal at m/z 578, which corresponds to the 
deprotonated molecule. Exact mass measurement of this signal (Table 1) provided the ion  
formula C26H25O12NCl. 
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Table 1. Ultra performance liquid chromatography-high resolution mass spectrometry 
(UHPLC-HRMS) data obtained from the four metabolites in HESI+ and HESI− mode. 
Compounds, polarity, chemical configuration, observed masses, calculated masses and 
mass error of the molecular are reported. 
Compound Polarity Ion formula Observed m/z (Da) Calculated m/z (Da) Mass error (ppm)
1-3 + C26 H27 O12 N Cl 580.12042 580.12219 −0.59 
1-3 − C26 H25 O12 N Cl 578.10812 578.10651 2.14 
4 + C21 H21 O6 N Cl 418.10428 418.10574 −0.91 
4 − C21 H19 O6 N Cl 416.09120 416.09009 1.66 
Structural elucidation of this compound was accomplished through product ion measurements by 
UHPLC-MS/MS analysis, and MSn experiments by LC ion trap MS. The product ion spectrum of  
[M − H]− (Figure 2a) showed four fragments at m/z 402, 358, 175 and 113. The fragments at m/z 175 
and 113 are known to be diagnostic ions of glucuronate moieties [36], so it is reasonable to suppose that 
Compound 1 should correspond to a glucuronidated OTA. The fragment with m/z 402 is the negative 
ion [M − H]− of OTA. The fragment ion at m/z 358 results from a neutral loss of CO2, revealing the 
presence of a carboxylic group, which is in agreement with previous data for OTA  
fragmentation [21,37–39]. 
Figure 2. Product ion spectra of Compound 1 (a); Compound 2 (b); Compound 3 (c); and 
Compound 4 (d) using ultra performance liquid chromatography-tandem mass spectrometry 
(UPLC-MS/MS).  
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Positive full-scan spectra of Compound 1 showed the ion at m/z 580 corresponded to [M + H]+, 
which was also confirmed by UHPLC-HRMS measurements, as shown in Table 1. 
The product ion spectrum of [M + H]+ showed different fragments. The protonated glucuronide first 
lost water and formed the fragment with m/z 562. Commonly, the product ion scan of glucuronide 
conjugates by LC-MS/MS provides the neutral loss of 176 Da (dehydrated glucuronic acid) due to the 
cleavage of glycosidic bond, with charge retention by the aglycone moiety. Therefore, as shown in 
Figure 3a, the mass difference between the ions 580 and 404 (protonated OTA ion), as well as between 
the fragments 562 and 386, corresponded to 176. The protonated ion at m/z 386, through losing CO, 
formed the fragments at m/z 358 (Figure 3a).  
Figure 3. MSn spectra of Compounds 1–3 (a, b, c) and Compound 4 (d, e, f).  
(a) MS2 (+) 580; (b) MS3 (+) 580→562; (c) MS4 (+) 580→562→404; (d) MS2 (+) 418;  
(e) MS3 (+) 418→386; (f) MS4 (+) 418→386→358 using LC ion trap MS. 
 
2.2. Compounds 2 and 3 
The negative full scan showing the deprotonated molecules (m/z 578) of Compounds 2 and 3 were 
isobaric with the [M − H]− of Compound 1, and therefore exhibited the same ion formula 
C26H25O12NCl (Table 1). The product ion spectrum of [M − H]− also showed the same fragments of 
m/z 402, 358, 175 and 113. Meanwhile, under the ESI+ mode, the same data on the full scan and 
product ions indicated that Compounds 1, 2 and 3 were isomers, which all belonged to the OTA 
glucuronide conjugates.  
2.3. Acylic, Phenolic and Amino Glucuronides 
OTA has three possible glucuronidation sites; in fact, it could form a phenol-, an acyl- or an  
amino-glucuronide. As shown in Figure 1, only small amounts of Compounds 1–3 were found 
indicating the low transformation rate from OTA to OTA-glucuronides. All three compounds were 
unknown and in order to characterize these isomers, different paths including retention times, literature 
references, MS/MS spectra and non-specific hydrolysis with β-glucuronidase were exploited in this work. 
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In the chromatographic separation (Figure 1), Compound 1 eluted at a retention time of 7.751 min, 
0.785 min less than Compound 2 and 0.978 min less than Compound 3. This means that 
Compound 1 is the most polar, Compound 2 a bit less and Compound 3 the least polar. From the 
structure, OTA amino-glucuronide contained one carboxylic group and one phenolic hydroxyl group, 
so it should be more polar than OTA phenol-glucuronide or acyl-glucuronide. Compared to OTA 
phenol-glucuronide containing one carboxylic group, OTA acyl-glucuronide should be less polar due to 
only one phenolic hydroxyl group. Therefore, Compound 1 was proposed to be OTA amino-glucuronide, 
Compound 2 was OTA phenol-glucuronide and the last one was OTA acyl-glucuronide. 
The subsequent analyses of negative electrospray ionization mode (ESI−) product ions of the three 
compounds showed that besides the characteristic fragments (m/z 175 and 113) of glucuronate 
moieties, an intense peak at m/z 193 corresponding to the glucuronate anion was observed in the 
spectra of Compound 3 (Figure 2c). The proposed fragmentation pathways of the three glucuronide 
conjugates are shown in Figure 4. For Compound 1 and Compound 2, the ions at m/z 193 could not be 
found; as a consequence, the proposed pathway also assigned the structure of acyl-glucuronide to 
Compound 3. Similar results have been obtained in the previous reports for the other glucuronide 
conjugates, according to which, in the negative MS2 spectrum of acyl-glucuronide conjugates, the base 
peak fragment was the glucuronate anion at m/z 193 [36,40–42]. To the best of our knowledge, this is 
the first report to provide direct evidence for OTA-glucuronide generation. 
Figure 4. The proposed fragmentation pathways for Compounds 1–3. 
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Hydrolysis of the glucuronide conjugates was performed to provide more information for definite 
identification of the three compounds. The enzyme could hydrolyze the amino-, phenol- and  
acyl-glucuronide. The contents of the targeted analytes were accurately quantified by the established 
LC-MS/MS using the standard purified version in the present study. The parameters and collision 
energies of precursor ions and product ions selected for the analysis are listed in Table 2. The results 
demonstrated that after hydrolysis by β-glucuronidase, a significant signal decrease was clearly 
observed for all three compounds with similar extents, indicating their glucuronide forms (Figure S-1, 
Supplementary Data). 
Table 2. The parameters and collision energies of precursor ions, product ions for the 
targeted analytes. 
Names 
Precursor 
ion (m/z) 
Primary 
product 
ion (m/z)
Collision 
energy (eV)
Secondary 
product ion 
(m/z) 
Collision 
energy (eV) 
Ionizatio
n mode 
Compound 1–3 580 358 20 239 38 ESI+ 
OTA methyl ester 418 358 18 239 32 ESI+ 
OTα 257 221 20 102 40 ESI+ 
2.4. Identification of Compound 4 
The positive and negative full-scan mass spectra analyzed showed the signal at m/z 580 and 578 
that corresponded to the protonated and deprotonated molecules, respectively. Exact mass 
measurement of [M + H]− and [M − H]+ (Table 1) provided the ion formula C21H21O6NCl and 
C21H19O6NCl. After analysis by LC ion trap MS, typical fragments at m/z 386, 358, 341 and 239 
indicated that this compound was OTA methyl ester [37] (Figure 3d–f).  
Unambiguous confirmation of this compound was obtained by means of OTA methyl ester 
preparation and from mass spectral comparison. The multiple reaction monitoring (MRM) method was 
established using the obtained standards (Table 2). The transformation rate from OTA to OTA methyl 
ester was almost 95% (Figure S-2, Supplementary Data). Then, Reaction 1 and Reaction 2 solutions 
were analyzed by the established method, and OTA methyl ester was clearly identified. Although a 
little amount of OTA methyl ester could be found in Reaction 3, the quantity was less than 5% of that 
in Reaction 1 or 2, in addition to the fact that no OTA methyl was found in Reaction 4, indicating that 
OTA methyl was not an artifact but produced by this reaction (Figure S-3, Supplementary Data). The 
reaction conditions in the present study were favorable for the glucuronidation biotransformation 
resulting in the production of OTA-glucuronides, while esterification reaction in principle could not be 
catalyzed by microsomes. However, in the present study, it was clearly demonstrated that OTA methyl 
ester could be produced with relative high content.  
2.5. Identification of OTα 
As reported, OTα is a very important metabolite [43,44]. However, it was not found in the reaction 
solution in full scan MS mode. A MRM method for detection of OTα was established by direct 
injection of the standard solution (1 μg mL−1), with the parameters indicated in Table 2. The solutions 
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of Reactions 1 and 2 before and after hydrolysis were analyzed by the established MRM method. The 
results showed that a very low content of OTα was present in the solutions of Reactions 1, 2 and 3, 
however, after hydrolysis, the concentration of OTα in Reactions 1 and 2 significantly increased 
(Figure S-4, Supplementary Data), indicating the existence of OTα-glucuronide formed by the 
glucuronidation transformation. It is not surprising that OTα, a major metabolite in vivo, was hardly 
found in incubations with liver microsomes, since hydrolysis is known to occur in the gut. When 
peptide cleavage occurs by an unspecific hydrolytic activity in the reaction mixture, OTα is then 
apparently further conjugated by microsomal UGTs in Reactions 1 and 2. As hydrolysis but not 
conjugation could occur in Reaction 3, however, a low content of OTα was also found in Mixture 3. 
2.6. Proposed Metabolic Pathways 
Based on the above observations, the in vitro metabolic profile of OTA via biotransformation by rat 
liver microsomes is proposed in Figure 5. First, the glucuronidation reaction could occur. There are 
three possible glucuronidation sites, and OTA has been transformed to phenol-, acyl- and an  
amino-glucuronide. Second, the Phase I methylation reaction could happen on OTA under such 
conditions, and a relatively high amount of OTA methyl ester was formed. Last but not least, 
hydrolysis could occur and OTA was conversed to OTα. The site of hydrolysis was tentatively 
proposed to be N-C9. Then, OTα was glucuronidated to form OTα-glucuronide. On the other side, 
OTA-glucuronides also might be directly hydrolyzed to form OTα-glucuronide.  
Figure 5. The proposed metabolic pathway for ochratoxin A (OTA) via glucuronidation by 
rat liver microsomes. 
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3. Experimental Section 
3.1. Chemicals and Reagents 
Methanol and acetonitrile were ultra-high performance liquid chromatography-mass 
spectrometry (UHPLC-MS) grade from Biosolve (Valkenswaard, the Netherlands). Water was 
purified by a Milli-Q system (Millipore, Brussels, Belgium). Ammonium acetate (AmAc), 
ammonium formate (AF), formic acid (FA), uridine 5’-diphosphoglucuronic acid trisodium salt 
(UDPGA), uridine 5’-diphospho-N-acetylgalactosamine disodium salt (UDPAG), anhydrous 
magnesium chloride (MgCl2) and 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris) were from 
Sigma-Aldrich (Saint Louis, MO, USA). β-glucuronidase and microsomes (pooled from male rat liver) 
were from Sigma-Aldrich (Saint Louis, MO, USA). 
Ochratoxin A (OTA) and ochratoxin α (OTα) were from Coring System Diagnostix GmbH 
(Gernshein, Germany). Accurately weighed solid portions of OTA and OTα standards were dissolved 
in acetonitrile to prepare 0.5 mg mL−1 of stock solutions. 
The OTA methyl ester was prepared according to the previous report with a minor modification [45]. 
The OTA standard solution (0.5 mL) was mixed with 9 mL of methanol and 0.5 mL of 12 N HCl, and 
incubated for 24 h at room temperature. Afterwards, 2.5 mL of extracts were dried under a nitrogen 
stream, redissolved with 1.5 mL of methanol and ready for analysis. 
3.2. UHPLC-MS/MS Analysis 
The LC system consisted of an Acquity UPLC® H-class (Waters, Milford, MA, USA). The 
compounds were separated on an Acquity® UPLC HSS T3 column (100 mm × 2.1 mm, 1.7 μm) at 40 
°C, with a mobile phase flow rate of 0.5 mL min−1. The mobile phase consisted of (A) 10 mmol L−1 
ammonium acetate solution, (B) water and (C) methanol. A linear gradient elution program was 
applied as follows: 0 min 1% A and 29% C, 10 min 1% A and 59% C, 10.2 min 1% A and 99% C, 11 
min 1% A and 99% C, 11.8 min 1% A and 29% C, and hold on for a further 2.2 min for  
re-equilibration, giving a total run time of 13 min. The injection volume was 5.0 μL (partial loop with 
needle overfill).  
A XEVO TQ-S® mass spectrometer (Waters) was used for the analysis of the target compounds. 
Full scan analysis was performed both in the positive electrospray ionization mode (ESI+) and the 
negative electrospray ionization (ESI−) mode. The following settings were used: source temperature, 
150 °C; desolvation temperature, 500 °C, scan range, m/z 100–1000, inter-scan delay, 0.01 s. The cone 
and desolvation gas flows were 30 and 1,000 L h−1, respectively. Data acquisition and processing were 
performed using MassLynx v4.1 (Waters).  
3.3. UHPLC-Orbitrap-HRMS Analysis 
UHPLC-ExactiveTM Benchtop Orbitrap mass spectrometer (Thermo Fisher Scientific, San José, 
CA, USA) analysis in the full scan mode (m/z, 100–1000) was utilized for the metabolic profiling 
study. Chromatographic separation was achieved on a Zorbax Eclipse Plus C18 column (100 mm × 2.1 mm, 
1.8 μm) at 30 °C, with a mobile phase flow rate of 0.4 mL min−1. The mobile phase consisted of (A) 
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water/methanol (5/95, v/v) containing 0.1% formic acid and 10 mM ammonium formate and (B) 
water/methanol (95/5, v/v) containing 0.1% formic acid and 10 mM ammonium formate. A linear 
gradient elution program was applied as follows: 0 min 0% B, 0.5 min 0% B, 20 min 99.1% B, 21 min 
99.1% B, 24 min 0% B and hold on for a further 4 min for re-equilibration, giving a total run time of 
28 min. The injection volume was 5.0 μL. The mass spectrometer was operated both in HESI+ and in 
HESI−. The following settings were used: spray voltage, 4.5 kV; capillary temperature, 250 °C; heater 
temperature, 250 °C; sheath gas flow, 45 a.u.; auxiliary gas, 10 a.u; sweep gas, 2 a.u., resolution 
100000 FWHM at 1 Hz (1 scan per second). The automatic gain control (AGC) target was set at high 
dynamic range (3e6), and the maximum injection time was 20 ms. Initial instrument calibration was 
achieved by infusing calibration mixtures (Thermo Fisher Scientific) for positive and negative ion 
modes. The positive calibration mixture included caffeine, Met-Arg-Phe-Ala acetate salt (MRFA) and 
Ultramark 1621®, while the negative calibration solution comprised sodium dodecyl sulfate, sodium 
taurocholate and Ultramark 1621®. These compounds were dissolved in a mixture of acetonitrile, water 
and methanol, and both mixtures were infused with a Chemyx Fusion 100 syringe pump (Thermo 
Fisher Scientific). Data were acquired and processed by Xcalibur 2.1 and Sieve 2.0 software (Thermo 
Fisher Scientific, Brookfield, Los Angeles, CA, USA). 
3.4. LC-Ion-Trap Analysis 
HPLC-ion-trap-MS system (Thermo Fisher Scientific) was used for the fragments analysis of the 
targeted analytes. The column used was an X-bridge C18 column (3.5 μm, 2.1 × 150 mm), supplied by 
Waters (Milford, MA, USA). The mobile phase consisted of (A) water/methanol (5/95, v/v) containing 
0.1% formic acid and 10 mM ammonium formate and (B) water/methanol (95/5, v/v) containing  
0.1% formic acid and 10 mM ammonium formate. The linear gradient elution program for LC-Ion-trap 
analysis was: 0–1 min B = 50%, 1–13 min B = 50%–97%, 13–18 min B = 97%, 18–19 min B = 97%–50%, 
and hold on for a further 6 min for re-equilibration, giving a total run time of 25 min. The mass 
spectrometer was operated both in HESI+ and in HESI− with the following settings: source voltage of  
5 kV, capillary temperature of 250 °C; heater temperature of 175 °C; sheath gas flow of 45 a.u.; aux 
gas of 10 a.u. The Xcalibur 2.0.7 software (Thermo Scientific) was used for instrument control, data 
acquisition and processing. 
3.5. Model Reactions 
The in vitro metabolic study of OTA via glucuronidation biotransformation by rat liver microsomes 
(Sigma-Aldrich, Saint Louis, MO, USA) was performed based on a slightly modified procedure 
adopted from Wu et al. [46] and Welsch et al. [35] for synthesis of DON-glucuronides. 
Reaction 1: An aliquot of OTA stock solution (241.8 μL, 0.3 μM) was transferred into a 5 mL tube 
and dried by nitrogen gas under 40 °C. Next, 15 μM of UDPGA, 0.25 μM of UDPAG and 5 μM of 
MgCl2 were added and all these reagents were dissolved in 400 μL of 50 mM Tris-HCl buffer (pH = 7.4). 
Rat liver microsomes (100 μL) were firstly mixed with 5 μg of alamethicin and kept on ice for 10 min 
before adding into the tubes. Then, the 500 μL reaction mixture was inverted a few times and 
incubated at 37 °C in a water bath for 1.5 h. The reaction was terminated by addition of 1 mL of 
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methanol, vortexed for 30 s and centrifuged at 14,000 rpm for 10 min. The supernatant (100 µL) was 
diluted with 900 μL of methanol/water solution (20/80, v/v) and was ready for injection. 
Reaction 2: An aliquot of OTA stock solution (241.8 μL, 0.3 μM) was transferred to a 5 mL tube 
and dried by nitrogen gas under 40 °C. Next, 15 μM of UDPGA, 0.25 μM of UDPAG and 5 μM of MgCl2 
were added and all these reagents were dissolved in 400 μL of 50 mM Tris-HCl buffer (pH = 7.4). Then 
100 μL (~2 mg of microsomal protein) of rat liver microsomes were added. The reaction mixture  
(500 μL) was subsequently pretreated as reaction 1. 
Reaction 3: A blank reaction was performed using the same procedure and ingredients as in 
reaction 2, except for UDPGA.  
Reaction 4: A control reaction was also performed using the same procedure and ingredients as in 
Reaction 2, except for OTA.  
3.6. Hydrolysis of the Glucuronides 
Hydrolysis of the reaction solution was performed for further identification of the OTA-glucuronides. 
An aliquot of the reaction solution (10 μL) was incubated with β-glucuronidase (1.5 units/reaction) 
(type IX, from E. coli, Sigma-Aldrich, Saint Louis, MO, USA) at 37 °C in 0.25 mL of 0.1 M NaAc 
buffer (pH = 5) for 18 h. The reaction was terminated by addition of 1 mL methanol, vortexed for 30 s 
and centrifuged at 14,000 rpm for 10 min. The supernatant was passed through a 0.22 μm nylon filter 
and was ready for injection  
4. Conclusions 
To address the remaining uncertainties regarding OTA biotransformation by liver microsomes, 
UHPLC-MS/MS, UHPLC-Orbitrap-HRMS and LC-ion-trap were applied as combined strategies to 
investigate the metabolic profile of OTA via glucuronidation by rat liver microsomes. Three different 
OTA glucuronide conjugates, which corresponded to OTA amino-glucuronide, OTA phenol-glucuronide 
and OTA acyl-glucuronide were clearly identified. The suggested structures were supported by the 
fragments observed in the mass spectrometers and by hydrolysis with β-glucuronidase. OTA methyl 
ester, OTα and OTα-glucuronide were formed in the same reaction mixture. A possible in vitro 
biotransformation pathway of OTA in rat microsomes was proposed. The results obtained here will help 
to have deeper understanding on the theoretical basis of OTA clinical toxicology. 
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